000319692 000__ 09743cam\a22004094a\4500
000319692 001__ 319692
000319692 005__ 20210513115456.0
000319692 008__ 070130s2007\\\\dcua\\\\\bf\\\001\0\eng\\
000319692 010__ $$a  2007004385
000319692 020__ $$a9781585623174 (pbk. : alk. paper)
000319692 020__ $$a1585623172 (pbk. : alk. paper)
000319692 035__ $$a(OCoLC)ocm81944018
000319692 035__ $$a319692
000319692 040__ $$aDNLM/DLC$$cDLC$$dBAKER$$dNLM$$dUKM$$dBTCTA$$dC#P$$dYDXCP$$dNOR$$dNLGGC
000319692 042__ $$apcc
000319692 049__ $$aISEA
000319692 05000 $$aRM315$$b.S37 2007
000319692 08200 $$a616.89/18$$222
000319692 1001_ $$aSchatzberg, Alan F.
000319692 24510 $$aManual of clinical psychopharmacology /$$cAlan F. Schatzberg, Jonathan O. Cole, Charles DeBattista.
000319692 250__ $$a6th ed.
000319692 260__ $$aWashington, DC :$$bAmerican Psychiatric Pub.,$$cc2007.
000319692 300__ $$axxv, 697 p. :$$bill. ;$$c21 cm.
000319692 504__ $$aIncludes bibliographical references (p. 645-646) and index.
000319692 50500 $$tPreface --$$g1.$$tGeneral principles of psychopharmacological treatment --$$tGeneral advice --$$tPractice guidelines --$$tLegal, ethical, and economic issues --$$tBibliography --$$g2.$$tDiagnosis and classifiction --$$tModd disorders --$$tBipolar disorders --$$tDepressive disorders --$$tSchizophrenia and other schizophrenia spectrum disorders --$$tAnxiety disorders --$$tSomatoform disorders --$$tPersonality disorders --$$tPsychoactive substance use disorders --$$tChild and adolescent disorders  --$$tFDA approval of symptom reduction strategies --$$tDSM-V and pharmacogenetics --$$tSummary --$$tBibliography --$$g3.$$tAntidepressants --$$tHistory --$$tGeneral priciples of antidepressant use --$$tChoosing an antidepressant --$$tDosage and administration --$$tDuration of treatment --$$tSelective serotonin reuptake inhibitors --$$tPharmacological effects --$$tIndications --$$tSide effects --$$tOverdose --$$tDrug interactions --$$tDosage and administration --$$tDiscontinuation --$$t5-HT₂ receptor antagonists (Trazodone and Nefazodone) --$$tPharmacological effects --$$tIndications --$$tSide effects --$$tOverdose --$$tDrug interactions --$$tDosage and admdinistration --$$tDiscontinuation --
000319692 50500 $$tSelective serotonin-norepinephrine reuptake inhibitors (Venlafaxine and Duloxetine) --$$tPharmacological effects --$$tIndications --$$tSide effects --$$tOverdose --$$tDrug interactions --$$tDosage and administration --$$tDiscontinuation --$$tCombined noradrenergic-dopaminergic antidepressant (Bupropion) --$$tPharmacological effects --$$tIndications --$$tSide effects --$$tOverdose --$$tDrug interactions --$$tDosage and administration --$$tMirtazapine --$$tPharmacological effects --$$tIndications --$$tSide effects --$$tOverdose --$$tDrug interactions --$$tDosage and administration --$$tNorepinephrine reuptake inhibitors : reboxetine and atomoxetine --$$tPharmacological effects --$$tIndications --$$tSide effects --$$tOverdose --$$tDrug interactions --$$tDosage and administration --$$tDiscontinuation --$$tGepirone --$$tTricyclic and tetracyclic antidepressants --$$tStructures --$$tPharmacological effects --$$tIndications --$$tBlood levels --$$tSide effects --$$tOverdose --$$tDosage and administration --$$tDiscontinuation --$$tMonoamine oxidase inhibitors --$$tPharmacological effects --$$tIndications --$$tSide effects --$$tOverdose --$$tDrug interactions --$$tDosage and administration --$$tDiscontinuation --$$tSelective and reversible monoamine oxidase inhibitors --$$tMelatonin agonist-5-HT₂c antagonist --$$tNovel antidepressants --$$tBibliography --
000319692 50500 $$g4.$$tAntipsychotic drugs --$$gGeneral principles of antipsychotic use --$$gThe$$tdrugs --$$tEfficacy --$$tAcute antipsychotic treatment --$$tEarly inpatient treatment --$$tMaintenance drug therapy --$$tUse in other psychiatric disorders --$$tAtypical antipsychotics --$$tClozapine --$$tRisperidone --$$tOlanzapine --$$tQuetiapine --$$tZipradisone --$$tAripiprazole --$$tStandard (typical) antipsychotics --$$tSide effects --$$tHaloperidol decanoate --$$tOther options for treating negative symptoms --$$tAlternatives to antipsychotic therapy --$$tAntipsychotic drugs in development --$$tBibliography --$$g5.$$tMood stabilizers --$$tLithium --$$tHistory and indications --$$tPharmacological effects --$$tClinical indications --$$tSide effects --$$tPreparations --$$tDosage and administration --$$tUse in pregnancy --$$tLithium Information Center --$$tAnticonvulsants --$$tValproate --$$tCarbamazepine --$$tLamotrigine --$$tOther anticonvulsants --$$tAntipsycholtics --$$tBenzodiazepines --$$tCalcium channel blockers --$$tOmega-3 fatty acids --$$tBibliography --$$g6.$$tAntianxiety agents --$$tBenzodiazepines --$$tIndications --$$tPharmacological effects --$$tSubclasses --$$tDosage and administration --$$tWithdrawal --$$tSide effects --$$tOverdose --$$tAntidepressants --$$tAgoraphobia and panic --$$tGeneralized anxiety disorder --$$tSocial phobia --$$tBody dysmorphic disorder --$$tPosttraumatic stress disorder --$$tObsessive-compulsive disorder --$$tAnticonvulsants --$$tAntipsychotics --$$tNoradrenergic agents --$$tClinical indications --$$tDosage and administration --$$tSide effects --
000319692 50500 $$tAntihistamines --$$tBuspirone --$$tBarbiturates --$$tAmobarbital sodium (amytal) as a parenteral solution --$$tCatatonia --$$tMeprobamate --$$tBibliography --$$g7.$$tHypnotics --$$tInsomnia --$$tBehavioral approaches --$$tPharmacological approaches --$$tBenzodiazephine hypnotics --$$tNonbenzodiazephine hypnotics --$$tMelatonin receptor agonist : Remelteon --$$tSedative antihistamines and other nonbenzodiazepine psychoactive drugs with hypnotic properties --$$tBarbiturates --$$tNonbarbiturate hypnotics --$$tMethaqualone --$$tOver-the-counter sleeping agents --$$tL-tryptophan --$$tMelatonin --$$tValerian extract --$$tGeneral conclusions --$$tBibliography --$$g8.$$tStimulants and other fast-acting drugs --$$tAmphetamine abuse --$$tUses of stimulants --$$tAttention-deficit/hyperactivity disorder --$$tDepression --$$tAcquired immunodeficiency syndrome --$$tOther medical conditions --$$tDrug combinations --$$tPsychosis --$$tStimulant use versus abuse --$$tOther fast-acting drugs --$$tBibliography --
000319692 50500 $$g9.$$tAugmentation strategies for treatment-resistant disorders --$$tAugmentation strategies for depression --$$tLithium-antidepressant combinations --$$tThyroid supplement-antidepressant combinations --$$tEstrogen, DHEA, and testosterone combinations with antidepressants --$$tDopamine agonist-antidepressant combinations --$$tMonoamine precursor-antidepressant combinations --$$tSSRI combinations --$$tAntipsychotic-antidepressant combinations --$$tOther TCA combinations --$$tAugmentation strategies for bipolar disorder --$$tCombinations of two or more mood stabilizers --$$tMood stabilizer-antipsychotic combinations --$$tMood stabilizer-antidepressant combinations --$$tMood stabilizers and omega-3 fatty acids --$$tAugmentation strategies for schizophrenia --$$tCombinations of two antipsychotics --$$tCombinations of antidepressants and antipsychotics --$$tCombinations of mood stabilizers and antipsychotics --$$tOther augmentation strategies --$$tBibliography --$$g10.$$tEmergency room treatment --$$tAgitation and violence --$$tDepression and suicidality --$$tAcute psychotic reactions --$$tMixed psychotic reactions --$$tSchizophrenic, schizophreniform, and manic psychoses --$$tDelirium --$$tSevere anxiety --$$tStupor and catatonia --$$tEmergency room  referrals --$$tBibliography --
000319692 50500 $$g11.$$tPharmacotherapy for substance use disorders --$$tDrug testing --$$tStimulants --$$tOpiates --$$tDetoxification --$$tMaintenance --$$tSedatives and hypnotics --$$tDetoxification --$$tPentobarbital tolerance test --$$tBenzodiazepines --$$tAlcohol --$$tMaintenance treatment --$$tCannabis --$$tHallucinogens --$$tPhencyclidine --$$tBibliography --$$g12.$$tPharmacotherapy in special situations --$$tPregnancy --$$tPediatric psychopharmacology --$$tStimulants --$$tAntipsychotics --$$tAntidepressants --$$tMood stabilizers --$$tAntianxiety drugs --$$tGeriatric psychopharmacology --$$tAntidepressants --$$tHypnotics and anxiolytics --$$tMood stabilizers --$$tAntipsychotics --$$tMedications for dementia --$$tMedications for agitation --$$tMental retardation --$$tMedical conditions --$$tPsychiatric disorders resulting from medical illness --$$tPsychiatric disorders associated with nonpsychiatric drugs --$$tPsychiatric disorders complicated by medical disorders --$$tConclusion --$$tBibliography --
000319692 50500 $$g13.$$tHerbals and dietary supplements --$$tSt. John's Wort (Hypericum perforatum) --$$tUses --$$tMechanism of action --$$tSide effects and drug interactions --$$tDosage and administration --$$tOmega-3 fatty acids --$$tUses and mechanism of action --$$tSide effects and drug interactions --$$tDosage and administration --$$tKava (Piper methysticum) --$$tUses --$$tMechanism of action --$$tSide effects and drug interactions --$$tDosage and administration --$$tValerian (Valeriana officinalis) --$$tUses --$$tMechanism of action --$$tSide effects and drug interactions --$$tDosage and administration --$$tGinkgo (Ginkgo biloba) --$$tUses --$$tMechanism of action --$$tSide effects and drug interactions --$$tDosage and administration --$$tFolate and B vitamins --$$tS-adenosylmethionine (SAMe) --$$tUses --$$tMechanism of action --$$tSide effects and drug interactions --$$tDosage and administration --$$tInositol --$$tUses --$$tMechanism of action --$$tSide effects and drug interactions --$$tDosage and administration --
000319692 50500 $$tDHEA (dehydroepiandrosterone) --$$tUses --$$tMechanism of action --$$tSide effects and drug interactions --$$tDosage and administration --$$tBibliography --$$tAppendix A : Strengths and costs of antidepressant and antipsychotic drugs --$$tAppendix B : Suggested readings --$$tIndex.
000319692 650_0 $$aPsychopharmacology$$vHandbooks, manuals, etc.
000319692 650_0 $$aPsychotropic drugs$$vHandbooks, manuals, etc.
000319692 7001_ $$aCole, Jonathan O.
000319692 7001_ $$aDeBattista, Charles.
000319692 85200 $$bgen$$hRM315$$i.S37$$i2007
000319692 85641 $$3Table of contents only$$uhttp://www.loc.gov/catdir/toc/ecip0710/2007004385.html
000319692 909CO $$ooai:library.usi.edu:319692$$pGLOBAL_SET
000319692 980__ $$aBIB
000319692 980__ $$aBOOK